PL Lodz Watala C: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
|info=[[IOC61]], [http://www.oroboros.at/?IOC55-56 IOC55-56] | |info=[[IOC61]], [http://www.oroboros.at/?IOC55-56 IOC55-56] | ||
}} | }} | ||
== Areas of interest == | |||
* Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis) | * Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis) | ||
* Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | * Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | ||
* Targeting of biochemical and molecular burden of diabetes | * Targeting of biochemical and molecular burden of diabetes | ||
== Gentle Science == | |||
* Link to [[Talk:Gentle_Science#Erich_Gnaiger_2012-10-28|Gentle Science]]. | |||
Revision as of 23:35, 28 October 2012
Areas of interest
- Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis)
- Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity
- Targeting of biochemical and molecular burden of diabetes
Gentle Science
- Link to Gentle Science.
